Swiss National Bank Sells 122,100 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Swiss National Bank reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,501,700 shares of the company’s stock after selling 122,100 shares during the quarter. Swiss National Bank’s holdings in Teva Pharmaceutical Industries were worth $36,558,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after purchasing an additional 2,180 shares during the last quarter. Signaturefd LLC lifted its stake in shares of Teva Pharmaceutical Industries by 90.8% in the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock valued at $51,000 after purchasing an additional 2,394 shares during the period. Desjardins Global Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 15.2% during the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after purchasing an additional 1,070 shares in the last quarter. Schechter Investment Advisors LLC acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $117,000. Finally, DGS Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $119,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $13.96 on Wednesday. The stock’s 50-day simple moving average is $13.64 and its two-hundred day simple moving average is $11.69. The firm has a market capitalization of $15.65 billion, a P/E ratio of -29.70, a P/E/G ratio of 1.67 and a beta of 1.04. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a twelve month low of $7.09 and a twelve month high of $14.47.

Insider Activity

In other news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the transaction, the vice president now directly owns 1 shares of the company’s stock, valued at $13.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 358,972 shares of company stock worth $4,739,820. 0.55% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TEVA shares. Barclays increased their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a report on Friday, March 8th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price target for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Finally, The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.